ST. VINCENT HOSPITAL & HCC
- Type
- Teaching hospital
- Where
- INDIANAPOLIS, IN
- Medicare CCN
- 150084
- Received
- $1,391,705 in 176 records, 2019 ($262,814 general, $1,128,890 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 70 | $262,814 |
| 2019 | Research payment | 106 | $1,128,890 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 106 | $1,128,890 |
| Grant | 6 | $176,955 |
| Gift | 6 | $31,090 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 26 | $29,280 |
| Space rental or facility fees (teaching hospital only) | 15 | $10,710 |
| Charitable Contribution | 4 | $7,270 |
| Education | 11 | $5,861 |
| Travel and Lodging | 1 | $1,340 |
| Food and Beverage | 1 | $304 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $4,188 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $3,094 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,610 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | AstraZeneca Pharmaceuticals LP | $2,093 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-12-31 | Linvatec Corporation | $605 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $270 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Abbott Laboratories | $150 | Research payment | In-kind items and services | TriClip Tricuspid Repair Device Device, Cardiac Arrhythmias and Heart Failure | TRILUMINATE Pivotal Trial | 2019 |
| 2019-12-31 | Masimo Corporation | $128 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Abbott Laboratories | $105 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-12-31 | Edwards Lifesciences Corporation | $92 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Edwards Lifesciences Corporation | $60 | Education | In-kind items and services | EV1000 Clinical Platform Device, Minimally Invasive Hemodynamic Monitoring | 2019 | |
| 2019-12-31 | Abbott Laboratories | $45 | Research payment | In-kind items and services | TriClip Tricuspid Repair Device Device, Cardiac Arrhythmias and Heart Failure | TRILUMINATE Pivotal Trial | 2019 |
| 2019-12-18 | ACUMED LLC | $1,100 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-18 | ACUMED LLC | $640 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-18 | ACUMED LLC | $560 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-18 | ACUMED LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-18 | ACUMED LLC | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-18 | ACUMED LLC | $32 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, Hand & Wrist | 2019 | |
| 2019-12-16 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-12-04 | Biosense Webster, Inc. | $20,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-26 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-11-06 | Surmodics, Inc. | $1,353 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-11-04 | Abbott Laboratories | $21 | Research payment | In-kind items and services | HeartMate II LVAS Device, Cardiac Arrhythmias and Heart Failure | HM3 SWIFT Study | 2019 |
| 2019-10-31 | TESARO, Inc. | $86,420 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-10-22 | Welch Allyn | $299 | Gift | Cash or cash equivalent | 2019 | ||
| 2019-10-22 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-16 | TESARO, Inc. | $35,184 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-10-16 | PFIZER INC. | $1,600 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-10-10 | Osteomed LLC | $2,250 | Grant | Cash or cash equivalent | Device, EXT-OTHER | 2019 | |
| 2019-10-09 | Stryker Corporation | $2,794 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $385 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $191 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $164 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-04 | Genentech, Inc. | $841 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-10-02 | Pharmacyclics LLC, an AbbVie Company | $1,750 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-10-02 | FUJIFILM SonoSite, Inc. | $149 | Education | In-kind items and services | S II Ultrasound System Device, Medical Device | 2019 | |
| 2019-09-27 | TESARO, Inc. | $500 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-09-24 | TESARO, Inc. | $91,620 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-09-24 | TESARO, Inc. | $13,906 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-11 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-09-05 | TESARO, Inc. | $69,136 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-09-05 | TESARO, Inc. | $700 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-08-30 | TESARO, Inc. | $518 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-08-29 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr | 2019 | |
| 2019-08-29 | TESARO, Inc. | $964 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-08-26 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ROTATEQ Biological, VACCINE | 2019 | |
| 2019-08-21 | Genentech, Inc. | $1,627 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-08-15 | TESARO, Inc. | $1,400 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-08-13 | TESARO, Inc. | $1,750 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-08-12 | TESARO, Inc. | $86,420 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-07-31 | Alexion Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SOLIRIS Drug, Immunology | 2019 | |
| 2019-07-26 | KARL STORZ Endoscopy-America | $978 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 16 FR. FLEXIBLE VIDEO CYSTOSCOPE Device, UROLOGY | 2019 | |
| 2019-07-24 | TESARO, Inc. | $2,450 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-07-17 | PFIZER INC. | $744 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-17 | Surmodics, Inc. | $700 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-07-17 | PFIZER INC. | $416 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-17 | PFIZER INC. | $96 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-17 | PFIZER INC. | $64 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-07-16 | Stryker Corporation | $1,636 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $406 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $219 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $79 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-11 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-07-11 | Genentech, Inc. | $3,747 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-07-08 | Osteomed LLC | $2,250 | Grant | Cash or cash equivalent | Device, EXT-OTHER | 2019 | |
| 2019-07-04 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-06-30 | Abbott Laboratories | $360 | Research payment | In-kind items and services | Portico Resheathable Transcatheter Aortic Valve System Device, Cardiac Arrhythmias and Heart Failure | Portico IDE | 2019 |
| 2019-06-30 | Abbott Laboratories | $70 | Research payment | In-kind items and services | Heart Failure Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) | 2019 |
| 2019-06-27 | TESARO, Inc. | $2,500 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-06-26 | FUJIFILM SonoSite, Inc. | $339 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2019 | |
| 2019-06-21 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-06-20 | TESARO, Inc. | $17,284 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-06-20 | FUJIFILM SonoSite, Inc. | $339 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2019 | |
| 2019-06-18 | Abbott Laboratories | $4,322 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-06-18 | Abbott Laboratories | $2,990 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-06-07 | AXOGEN | $2,450 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-05-30 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-30 | SOBI, INC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYNAGIS Drug, Immunology | 2019 | |
| 2019-05-29 | Celgene Corporation | $27,750 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Celgene - Connect MM | 2019 |
| 2019-05-29 | FUJIFILM SonoSite, Inc. | $80 | Education | In-kind items and services | S II Ultrasound System Device, Medical Device | 2019 | |
| 2019-05-29 | PFIZER INC. | $37 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-05-28 | Becton, Dickinson and Company | $3,272 | Research payment | Cash or cash equivalent | A CLINICAL EVALUATION OF A NOVEL CATHETER COMPARED TO A CURRENTLY MARKETED CATHETER FOR MANAGING PLEURAL EFFUSIONS. | 2019 | |
| 2019-05-16 | TESARO, Inc. | $11,610 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER | 2019 |
| 2019-05-16 | Abbott Laboratories | $2,100 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-05-16 | Abbott Laboratories | $1,750 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-05-16 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-05-16 | Abbott Laboratories | $700 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-05-16 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-05-15 | Chiesi USA, Inc. | $1,000 | Charitable Contribution | Cash or cash equivalent | CUROSURF Drug, NEONATOLOGY | 2019 | |
| 2019-05-13 | Genentech, Inc. | $6,719 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-05-08 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-08 | TESARO, Inc. | $13,500 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-08 | TESARO, Inc. | $8,500 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-08 | TESARO, Inc. | $4,000 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-05-02 | Surmodics, Inc. | $900 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-05-02 | Surmodics, Inc. | $861 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-04-26 | AXOGEN | $2,450 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-26 | AXOGEN | $1,600 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-26 | AXOGEN | $700 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-26 | AXOGEN | $500 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-26 | AXOGEN | $500 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-26 | AXOGEN | $500 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-04-24 | Abbott Laboratories | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure | 2019 | |
| 2019-04-23 | TESARO, Inc. | $34,716 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-23 | Genentech, Inc. | $17,750 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-04-23 | Genentech, Inc. | $2,150 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-04-23 | ACELL, INC. | $1,210 | Education | Cash or cash equivalent | 2019 | ||
| 2019-04-22 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-19 | Alexion Pharmaceuticals, Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Strensiq Drug, Endocrinology | 2019 | |
| 2019-04-19 | Oticon Medical, LLC | $13 | Education | Cash or cash equivalent | PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device | 2019 | |
| 2019-04-18 | TESARO, Inc. | $5,334 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER | 2019 |
| 2019-04-18 | Chiesi USA, Inc. | $1,000 | Charitable Contribution | Cash or cash equivalent | CUROSURF Drug, NEONATOLOGY | 2019 | |
| 2019-04-18 | Chiesi USA, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CLEVIPREX Drug, CARDIOVASCULAR | 2019 | |
| 2019-04-15 | ACELL, INC. | $1,210 | Education | Cash or cash equivalent | 2019 | ||
| 2019-04-12 | Stryker Corporation | $1,508 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $427 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $160 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $70 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-11 | Abbott Laboratories | $28 | Research payment | In-kind items and services | HeartMate II LVAS Device, Cardiac Arrhythmias and Heart Failure | HM3 SWIFT Study | 2019 |
| 2019-04-10 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-04-04 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Axium and Proclaim Neurostimulator Systems Device, Cardiac Arrhythmias and Heart Failure | TARGET: A Post-Approval Study to Evaluate Targeted SCS (DRG) Stimulation for the management of Moderate to Severe Chroni | 2019 |
| 2019-04-03 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-04-02 | Varian Medical Systems, Inc. | $20,268 | Gift | In-kind items and services | 2019 | ||
| 2019-04-02 | SANOFI PASTEUR INC. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NO PRODUCT DISCUSSED Drug | 2019 | |
| 2019-04-02 | KARL STORZ Endoscopy-America | $630 | Gift | In-kind items and services | FLEXIBLE CYSTOSCOPE, CHNL:7FR, 15FRX37CM Device, UROLOGY | 2019 | |
| 2019-03-31 | Abbott Laboratories | $150 | Research payment | In-kind items and services | AMPLATZER Amulet Left Atrial Appendage Occlude Device, Cardiac Arrhythmias and Heart Failure | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2019 |
| 2019-03-28 | AstraZeneca Pharmaceuticals LP | $36,959 | Research payment | Cash or cash equivalent | LYNPARZA Drug, Oncology | A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Pati | 2019 |
| 2019-03-26 | Medtronic Vascular, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | HeartWare HVAD Device, Ventricular Assist Devices | 2019 | |
| 2019-03-26 | Pharmacyclics LLC, an AbbVie Company | $425 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-03-26 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-03-25 | PFIZER INC. | $149,600 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-03-25 | TESARO, Inc. | $17,284 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-03-21 | TESARO, Inc. | $5,000 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-03-21 | Abbott Laboratories | $4,731 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-21 | Abbott Laboratories | $775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-20 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-20 | PFIZER INC. | $197 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-13 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-03-12 | Abbott Laboratories | $1,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-12 | Abbott Laboratories | $795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-11 | Janssen Research & Development, LLC | $6,250 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Effic | 2019 | |
| 2019-03-11 | Abbott Laboratories | $2,687 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-11 | Abbott Laboratories | $1,045 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-11 | Abbott Laboratories | $360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-03-08 | Janssen Research & Development, LLC | $3,650 | Research payment | Cash or cash equivalent | A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Effic | 2019 | |
| 2019-03-07 | ACELL, INC. | $2,237 | Education | Cash or cash equivalent | 2019 | ||
| 2019-03-06 | PFIZER INC. | $136 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | A LONGTERM OPENLABEL EXTENSION STUDY OF TOFACITINIB CP690550 FOR THE TREATMENT OF PSORIATIC ARTHRITIS | 2019 |
| 2019-03-04 | PFIZER INC. | $197 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-02-28 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-02-26 | AXOGEN | $700 | Research payment | Cash or cash equivalent | Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair RECON | 2019 | |
| 2019-02-22 | Medline Industries LP | $5,000 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-02-15 | Pharmacyclics LLC, an AbbVie Company | $175 | Research payment | Cash or cash equivalent | Ibrutinib Drug, Oncology | PCYC-1134M-CA | 2019 |
| 2019-02-14 | TESARO, Inc. | $2,450 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS | 2019 |
| 2019-02-13 | Genentech, Inc. | $1,300 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-02-12 | ARRAY BIOPHARMA INC | $17,275 | Research payment | Cash or cash equivalent | Mektovi Drug, Melanoma | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Perit | 2019 |
| 2019-02-12 | Genentech, Inc. | $8,661 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-02-12 | ARRAY BIOPHARMA INC | $1,750 | Research payment | Cash or cash equivalent | Mektovi Drug, Melanoma | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Perit | 2019 |
| 2019-02-11 | TESARO, Inc. | $34,568 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-02-01 | Genentech, Inc. | $6,642 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-02-01 | Genentech, Inc. | $5,225 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2019 |
| 2019-01-31 | TESARO, Inc. | $3,150 | Research payment | Cash or cash equivalent | ZEJULA Drug, ONCOLOGY | A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER | 2019 |
| 2019-01-28 | Hill-Rom Company, Inc | $1,340 | Travel and Lodging | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-01-28 | Hill-Rom Company, Inc | $304 | Food and Beverage | In-kind items and services | Hill-Rom Heart and Respiration Rate Monitoring System powered by EarlySense Device, Breathing Frequency Monitor | 2019 | |
| 2019-01-25 | Janssen Research & Development, LLC | $700 | Research payment | Cash or cash equivalent | YONDELIS Drug, Oncology | A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for | 2019 |
| 2019-01-24 | Abbott Laboratories | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2019 | ||
| 2019-01-17 | TESARO, Inc. | $51,852 | Research payment | In-kind items and services | ZEJULA Drug, ONCOLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NIRAPARIB MAINTENANCE TREATMENT IN PATIENT | 2019 |
| 2019-01-17 | Osteomed LLC | $2,250 | Grant | Cash or cash equivalent | Device, EXT-OTHER | 2019 | |
| 2019-01-10 | E.R. Squibb & Sons, L.L.C. | $9,053 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | Phase III VTE Prev in Children w ALL | 2019 |
| 2019-01-08 | Stryker Corporation | $1,407 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $284 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $157 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-08 | Stryker Corporation | $82 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-01-03 | PFIZER INC. | $2,000 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-01-03 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 | |
| 2019-01-03 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Indianapolis city, IN, county Marion County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Indianapolis city, IN | County Marion County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 885,860 | 975,809 | 6,851,073 |
| Population, 2020 census P1 | 887,642 | 977,203 | 6,785,528 |
| Median age B01002 | 34.3 | 34.4 | 38.1 |
| Under 18 B01001 | 24.8% | 25.0% | 23.3% |
| 65 and over B01001 | 13.1% | 13.2% | 16.8% |
| Households B11001 | 362,961 | 400,432 | 2,716,009 |
| Foreign born B05002 | 12.7% | 12.6% | 6.3% |
| Median household income B19013 | $66,219 | $66,346 | $71,957 |
| Median family income B19113 | $82,766 | $83,024 | $90,767 |
| Per capita income B19301 | $37,680 | $37,704 | $38,351 |
| Poverty rate B17001 | 15.8% | 15.3% | 12.3% |
| Unemployment rate B23025 | 5.1% | 5.0% | 4.3% |
| Civilian labor force B23025 | 472,847 | 520,799 | 3,472,016 |
| Mean commute (minutes) B08013 | 24.6 | 24.5 | 24.1 |
| Bachelor's degree or higher B15003 | 34.9% | 34.8% | 29.5% |
| Housing units B25001 | 401,428 | 441,040 | 2,976,568 |
| Owner-occupied B25003 | 56.0% | 56.5% | 70.6% |
| Renters B25003 | 44.0% | 43.5% | 29.4% |
| Median home value B25077 | $224,800 | $224,000 | $218,200 |
| Median gross rent B25064 | $1,156 | $1,153 | $1,062 |
| White, not Hispanic B03002 | 48.9% | 49.5% | 75.4% |
| Black B03002 | 27.6% | 27.1% | 9.1% |
| Hispanic or Latino B03002 | 13.8% | 13.8% | 8.6% |
| Asian B03002 | 4.2% | 4.0% | 2.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Indianapolis city, IN.
Comments